dc.contributor.author | Tell, Grethe S. | |
dc.contributor.author | Frøyland, Livar | |
dc.contributor.author | Haugen, Margaretha | |
dc.contributor.author | Holvik, Kristin | |
dc.contributor.author | Løvik, Martinus | |
dc.contributor.author | Strand, Tor A | |
dc.contributor.author | Iversen, Per Ole | |
dc.coverage.spatial | Norway | nb_NO |
dc.date.accessioned | 2018-04-27T11:26:07Z | |
dc.date.available | 2018-04-27T11:26:07Z | |
dc.date.created | 2017-10-19T09:17:45Z | |
dc.date.issued | 2016 | |
dc.identifier.isbn | 978-82-8259-197-3 | |
dc.identifier.uri | http://hdl.handle.net/11250/2496375 | |
dc.description.abstract | The Norwegian Scientific Committee for Food Safety (VKM) has, at the request of the Norwegian Food Safety Authority, assessed the risk of specified doses of L-arginine and arginine alpha-ketoglutarate in food supplements. VKM concludes that:
In adults (≥18 years), the specified doses of 3000, 3500, 4000, 4500, 5000, 5500 and 6000 mg/day of arginine in food supplements are considered unlikely to cause adverse health effects. The dose 6800 mg/day may represent a risk of adverse health effects.
In adolescents (14 to <18 years), the specified doses 3000, 3500, 4000, 4500, 5000, 5500 mg/day L-arginine in food supplements are considered unlikely to cause adverse health effects, whereas the doses 6000 and 6800 mg/day may represent a risk of adverse health effects.
In children (10 to <14 years), the specified doses 3000 and 3500 mg/day L-arginine in food supplements are considered unlikely to cause adverse health effects, whereas the doses 4000, 4500, 5000, 5500, 6000 and 6800 mg/day may represent a risk of adverse health effect.
No dosage of arginine alpha-ketoglutarate in food supplements can be evaluated, due to lack of data. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | Norwegian Committee for Food Safety | nb_NO |
dc.relation.ispartof | VKM Report | |
dc.relation.ispartofseries | VKM Report; | |
dc.relation.uri | https://vkm.no/download/18.645b840415d03a2fe8f26066/1502798687898/8b62ea4db0.pdf | |
dc.rights | Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/deed.no | * |
dc.subject | Adverse health effect | nb_NO |
dc.subject | negative health effect | nb_NO |
dc.subject | Norwegian Scientific Committee for Food Safety | nb_NO |
dc.subject | Norwegian Food Safety Authority | nb_NO |
dc.subject | other substances | nb_NO |
dc.subject | risk assessment | nb_NO |
dc.subject | VKM | nb_NO |
dc.subject | L-arginine | nb_NO |
dc.subject | arginine alpha-ketoglutarate | nb_NO |
dc.subject | food supplement | nb_NO |
dc.title | Risk assessment of "other substances" - L-arginine and arginine alpha-ketoglutarate. Opinion of the Panel on Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientific Committee for Food Safety | nb_NO |
dc.type | Research report | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.source.pagenumber | 47 | nb_NO |
dc.source.issue | 7 | nb_NO |
dc.identifier.cristin | 1505773 | |
cristin.unitcode | 1991,0,0,0 | |
cristin.unitname | Sykehuset Innlandet HF | |
cristin.ispublished | true | |
cristin.fulltext | original | |